Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.

Luis Paz-Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee, Chia-Chi Lin, Maria Jose Flor, Massimo Di Nicola, Rosa Maria Alvarez, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, James L. Gulley, Byoung Chul Cho

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: The safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β "trap") fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1), was evaluated in patients with advanced NSCLC. METHODS: This expansion cohort of NCT02517398, an ongoing, phase 1, open-label trial, includes 80 patients with advanced NSCLC that progressed after platinum doublet therapy or after platinum-based adjuvant or neoadjuvant treatment and those who also have not received previous immunotherapy. Patients were randomized at a one-to-one ratio to receive either bintrafusp alfa 500 mg or the recommended phase 2 dosage of 1200 mg every 2 weeks. The primary end point was the best overall response (by Response Evaluation Criteria in Solid Tumors 1.1 as adjudicated by independent review committee) and was assessed by the objective response rate (ORR). RESULTS: A total of 80 patients were randomized to receive bintrafusp alfa 500 or 1200 mg (n = 40 each). Median follow-up was 51.9 weeks (IQR, 19.6-74.0). The ORR in all patients was 21.317 of 80). The ORR was 17.5seven of 40) and 25.010 of 40) for the 500 mg dose and the 1200 mg dose (recommended phase 2 dose), respectively. At the 1200 mg dose, patients with PD-L1-positive and PD-L1-high (≥80 had ORRs of 36.010 of 27) and 85.7six of seven), respectively. Treatment-related adverse events occurred in 55 of the 80 patients (69 and were graded as greater than or equal to 3 in 23 of the 80 patients (29. Of the 80 patients, eight (10 had a treatment-related adverse event that led to treatment discontinuation; no treatment-related deaths occurred. CONCLUSIONS: Bintrafusp alfa had encouraging efficacy and manageable tolerability in patients with NSCLC previously treated with platinum.
Original languageEnglish
JournalJournal of Thoracic Oncology
Issue number7
Publication statusPublished - Jul 1 2020

Fingerprint

Dive into the research topics of 'Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.'. Together they form a unique fingerprint.

Cite this